Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04040673 | RAman For Thyroid cancER(RAFTER) | withdrawn | — | 0 | Gloucestershire Hospitals NHS Foundation TrustOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05774535 | Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery(TIROVASC) | withdrawn | — | 0 | Istituto Auxologico ItalianoOTHER | 1 |
| Oct 2, 2025 |
| clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO) | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04868045 | Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Feb 21, 2023 | clinicaltrials |
| NCT00373711 | Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA | withdrawn | — | 0 | Stanford UniversityOTHER | 0 | Jun 21, 2022 | clinicaltrials |
| NCT04224792 | Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | withdrawn | Phase 2 | 0 | Antonio FojoOTHER | 0 | Oct 13, 2021 | clinicaltrials |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma | withdrawn | N/A | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT02390739 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01747512 | An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT) | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Nov 14, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT02726282 | Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT01994200 | Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients(ITCA-ThyCa) | withdrawn | Phase 1 / Phase 2 | 0 | Jewish General HospitalOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers(TAM-RT) | withdrawn | Phase 1 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT01153945 | Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum | withdrawn | — | 0 | Meir Medical CenterOTHER | 1 | Apr 7, 2015 | clinicaltrials |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer(FACT2) | withdrawn | Phase 3 | 0 | Mateon TherapeuticsINDUSTRY | 0 | May 1, 2014 | clinicaltrials |
| NCT00954837 | Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer(CYT2THYR) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | May 27, 2013 | clinicaltrials |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | withdrawn | Phase 2 | 0 | Eanm Research LtdNETWORK | 1 | May 17, 2013 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials